Topics

Articles

In order to succeed in today’s outcomes-driven healthcare landscape, pharmaceutical companies must move from traditional sales models to strategic, measurable partnerships with integrated delivery networks (IDNs).

Bridging the Gap Between Strategy and Practice in IDN Partnerships

Potential import taxes on pharma goods entering the United States continue to have effects on the industry in more ways than one. 

The Tariff Effect: Greater Supply Chain Prepares for Repercussions 

Direct-to-consumer and direct-to-patient models are major contributors. 

Why CX Is a Difference Maker for Pharma

This serialization system represents a business imperative that yields significant competitive advantages.

Serialization 2.0: Why It’s Time to Upgrade, and What’s at Stake

In an exclusive sit-down with Pharma Commerce, Anne Cassity, senior vice president of government affairs for the National Community Pharmacists Association (NCPA), discusses pending legislation that could affect the impact of PBM pricing. 

Limiting the Use of Spread Pricing

A Day 3 presentation dives into the impact of copay accumulators, maximizers, and AFPs on driving cost savings. 

Hubs East 2025: The Patient Access Landscape

The session provides an overview of the uninsured population, and also tackles challenges faced by patients when it comes to accessing PAPs.

PAP 2025: Understanding the Uninsured Landscape

A professor of food, pharma, and healthcare business at Saint Joseph’s University’s Erivan K. Haub School of Business.

This link in the pharma supply chain is undergoing a major transformation propelled by technological advancements, regulatory changes, and evolving market dynamics, requiring industry leaders to adopt innovative strategies in order to remain competitive.

Strategic Trends in Pharmaceutical Manufacturing for Industry Leaders

Videos

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Brad Stewart, BDO’s national life sciences co-leader, discusses how the tariffs impact the reshoring of manufacturing services, alongside the strategies that pharma leaders can use in order to start shoring up their supply chains.

The Case for Reshoring Manufacturing to the United States

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Geoffrey Joyce, PhD, director of health policy at the Leonard D. Schaeffer Center for Health Policy & Economics at USC, describes how PBMs financially benefit from generics, and why a completely open generic market powered by cash would be beneficial. 

Opinion